Company intelligence

Anew Labs

As of September 16, 2026, Anew Labs was last valued at $1.5B (TheNextWeb) and has raised at least $290M in equity across 1 sourced funding round.

Last verified Sep 16, 2026

Anew Labs at a glance

As of
Latest valuation
$1.5B[1]
September 2026Derived
Equity raised
$290M[2]
Across 1 sourced roundDerived
Lead investors
HongShan (Sequoia China)[3]
Funding round · September 2026
Founded
2021[4]
  1. [1] Latest valuation: TheNextWeb, September 16, 2026
  2. [2] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), September 16, 2026
  3. [3] Lead investors: TheNextWeb, September 16, 2026
  4. [4] Founded: pharmaphorum.com (retrieved October 19, 2026)

What Anew Labs does

Anew Labs is an AI drug discovery company spun off from ByteDance.[1] It is headquartered in Shanghai, with offices in San Francisco and Singapore, according to Reuters.[1] The company runs platforms for biomolecular structure prediction and design, antibody design and optimization, and drug discovery.[1] The team built structure-prediction and protein-design models including Protenix and PXDesign.[2] Its pipeline includes a small-molecule drug, a drug targeting a protein on the surface of human cells and two undisclosed targets.[1] One of its four candidates, an AI-designed IL-17 inhibitor, was presented in April 2026 at the American Association of Immunologists meeting in Boston.[2],[1] About 50 core staff moved to the new company with its algorithms, platform and pipeline assets, and ByteDance's Volcano Engine cloud continues to supply computing power.[2]

Is something wrong on this page?

Recent changes

  1. Sep 16, 2026Raised $290M at a $1.5B valuation TheNextWeb
  2. Sep 16, 2026First reported valuation: $1.5B TheNextWeb
  3. Sep 16, 2026New investor: IDG Capital TheNextWeb
  4. Sep 16, 2026New investor: Boyu Capital TheNextWeb
  5. Sep 16, 2026New investor: Hillhouse TheNextWeb
Earlier changes (3)
  1. Sep 16, 2026New investor: Primavera Capital TheNextWeb
  2. Sep 16, 2026New investor: HongShan (Sequoia China) TheNextWeb
  3. Sep 16, 2026ByteDance Spins Out AI Drug Unit Anew Labs At $1.5B Pulse story

Funding history

1 equity event · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Sep 16, 2026Funding round$290M$1.5Bpost-money
WithIDG CapitalHillhouseGaorong VenturesPrimavera CapitalBoyu Capitalunverified5Y CapitalShanghai Future Industries FundSBP Group
TheNextWeb

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

How Anew Labs has been funded

In September 2026 Reuters reported, citing people familiar with the matter, that Anew Labs completed a $290 million first external round at a $1.5 billion valuation.[1] HSG (formerly Sequoia China), IDG Capital and Hillhouse's GL Ventures led the round, with 5Y Capital as a co-lead.[1] ByteDance keeps a 56% stake after the round.[1]

Investors and their roles

  • The unit is led by Liu Kai, who spent seven years in venture capital at IDG Capital and Fire Stone Investment before joining ByteDance in 2021, according to Sina Finance as cited by The Next Web.[2]
  • Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group and the state-backed Shanghai Future Industries Fund also invested, the sources said.[1]

Investors

Latest Pulse

  1. ByteDance Spins Out AI Drug Unit Anew Labs At $1.5BByteDance closed a $290 million funding round for Anew Labs, its newly spun-off AI drug discovery unit, at a $1.5 billion valuation, with the TikTok parent retaining 56% ownership.→

Coverage Timeline

newest first
  1. Sep 16, 2026AIByteDance Spins Out AI Drug Unit Anew Labs At $1.5B$290M / $1.5B valuation→

All Coverage

Value Add Research

Related Companies

Anew Labs FAQ

What is Anew Labs's valuation?

In September 2026 Reuters reported, citing people familiar with the matter, that Anew Labs completed a $290 million first external round at a $1.5 billion valuation.[1]

Where is Anew Labs headquartered?

Anew Labs is headquartered in Shanghai, with offices in San Francisco and Singapore, according to Reuters.[1]

What does Anew Labs do?

Anew Labs is an AI drug discovery company spun off from ByteDance.[1]

How much has Anew Labs raised?

Anew Labs has raised at least $290M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $290M funding round in September 2026 at a $1.5B post-money valuation, reported by TheNextWeb. Debt financing, tender offers and secondary sales are not counted.

Who invested in Anew Labs?

Lead investors in Anew Labs's sourced funding rounds include HongShan (Sequoia China). Per round: its September 2026 funding round was led by HongShan (Sequoia China).

When was Anew Labs founded?

Anew Labs was founded in 2021, according to pharmaphorum.com.

References

researched 2026-10-23
  1. ksl.com
  2. The Next Web
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·